Law Offices of Howard G. Smith Reminds Investors of Lead Plaintiff Deadlines for CALX, AVAV, ZTS, LCID

Regulation
โดย GlobeNewswire·Read original
Summary · why it matters

The Law Offices of Howard G. Smith reminds investors that securities fraud class action lawsuits have been filed against Calix, AeroVironment, Zoetis, and Lucid Group, with lead plaintiff deadlines approaching in late July 2026. The Calix lawsuit alleges the company misled investors about margin benefits from advanced memory component purchases and subsequent negative margin pressure, with a lead plaintiff deadline of July 27, 2026. AeroVironment faces claims it understated competition risks related to the SCAR program and U.S. Space Force modernization efforts, also with a July 27 deadline. Zoetis is accused of concealing weakening veterinarian adoption of Librela, market share losses for Simparica Trio, and competitive pressures on Apoquel and Cytopoint, with the same July 27 deadline. The Lucid Group action, with a July 28 deadline, alleges the company failed to disclose a supplier quality issue that disrupted Lucid Gravity deliveries and negatively impacted financial results.

Impact on stocks 4

Defense & Geopolitical Fragmentation▼ · 1 stocks
AeroVironment Inc
AVAV
▼ NegativeCompetitionrelevance

Lawsuit alleges AeroVironment understated competition risks related to SCAR program and U.S. Space Force modernization.

Cloud & Digital Infrastructure▼ · 1 stocks
Calix Inc
CALX
▼ NegativePricingrelevance

Lawsuit alleges Calix misled investors about margin benefits from advanced memory component purchases and subsequent negative margin pressure.

Electrification & Mobility▼ · 1 stocks
Lucid Group Inc
LCID
▼ NegativeSupplyrelevance

Lawsuit alleges Lucid failed to disclose a supplier quality issue that disrupted Lucid Gravity deliveries and negatively impacted financial results.

Health Care▼ · 1 stocks
Zoetis Inc
ZTS
▼ NegativeDemandrelevance

Lawsuit alleges Zoetis concealed weakening veterinarian adoption of Librela, market share losses for Simparica Trio, and competitive pressures on Apoquel and Cytopoint.

© 2026 MarketDXNews